Trastuzumab deruxtecan

  • Biologic
  • Enhertu

Therapy management checklist

Screening, baseline and ongoing monitoring with the label's stated frequency, hold and discontinue criteria, and counseling points, each quoted from the FDA label.

Loading the therapy management checklist…

Storage and cold chain

Trastuzumab deruxtecan: storage and handling

Refrigerate
Yes, as the label states
Label statement
Store vials in a refrigerator at 2°C to 8°C (36°F to 46°F) in the original carton to protect from light until time of reconstitution.
Freezing
Do not freeze
Label statement
Do not freeze.
Room temperature
No allowance stated
Back into the refrigerator
Not addressed
Light
Protect from light
Label statement
Store vials in a refrigerator at 2°C to 8°C (36°F to 46°F) in the original carton to protect from light until time of reconstitution.
Shaking
Do not shake
Label statement
Do not shake the reconstituted or diluted solution [see Dosage and Administration (2.4) ] .

Temperature excursion helper

Answers only from this label's storage statements. It does not judge whether a product is still usable beyond what the label states.

The label does not state a room-temperature allowance for this product.

Entered: 1 day at up to 77°F (25°C).

Store vials in a refrigerator at 2°C to 8°C (36°F to 46°F) in the original carton to protect from light until time of reconstitution.
Do not freeze.

Contact the manufacturer about this product; the label text ClinDose has does not print a phone number for it.

All storage statements on the label (3)
  • Store vials in a refrigerator at 2°C to 8°C (36°F to 46°F) in the original carton to protect from light until time of reconstitution.
  • Do not freeze.
  • Do not shake the reconstituted or diluted solution [see Dosage and Administration (2.4) ] .

FDA label version 28, effective May 15, 2026. DailyMed

Dosing and titration calendar

Built only from the schedules the label states (loading, titration, day schedules, cycles and weight bands). Steps the label states in words the calendar cannot place are shown, not guessed.

Loading dosing schedules…

Medicare Part D coverage

No Part D formulary in the CMS files (2026Q3) lists this drug. It may be covered under Part B or not covered.

Patient assistance

No manufacturer program page is listed for this drug yet.

Independent foundations and the full directory (checked 2026-11-06). Eligibility and amounts are set by each program; open its page for them.

For licensed clinicians. Use with clinical judgment. Statements are quoted from the FDA label; confirm against the label for the product you are using.